

Korea Comprehensive Report



ABC Co., Ltd.

D-U-N-S: 68-111-1111

Inquiry Date : 2024/10/30

Delivery Date : 2024/11/07

Note:

1. The information in Korea Comprehensive Report was mainly obtained from a third party source. D&B reviews, verifies and enriches the information by checking historic records in D&B database, public media records, governmental files and/or conducting management interviews with subject.
2. This report, which is licensed under contract solely for use by D&B's customer as one factor in its business decisions, contains information compiled from sources D&B does not control and which, unless otherwise indicated in this report, have not been verified. D&B does not assume any of user's business risk; does not guarantee the accuracy, completeness, and timeliness of the information; and shall not be liable in tort, contract or otherwise for any loss, damage, and injury resulting from use of this information, even if caused by D&B's negligence.
3. Please contact your local customer service center if you are not able to see this report using your application.

16F, B Core , Seoul Central Post Office Bldg., 70, Sogong-ro, Jung-gu, Seoul

Tel:(822)2122-2586

Fax:(822)2122-2590

<http://www.nicednb.com>

NICE D&B Co., Ltd.

Company Summary

Company Name	ABC Co., Ltd.		
President(CEO)	Hong, Gil Dong	Established Date	1954/04/27
DUNS Number	68-111-1111	Registered Date	1958/08/19
Business Registration No.	123-45-67890	Corporate Registration No.	110111-1000000
Address	***, Teheran-ro, Gangnam-gu, Seoul		
D&B Rating	5A1 (Prev. 5A1)	CLIP Risk Rating	A (Prev. A)
Failure Score Class	3	History	Clear
Condition	Strong	Trend	Even
No. of Employee	1,002 Person	Sales Account	KRW 518,002 Mil.
Net Income	KRW -2,151 Mil.	Total Assets	KRW 838,744 Mil.
Issued Capital	KRW 6,882 mil.	Settle Accounts Month	12
Telephone	+82-2-527-****	FAX	+82-2-527-****
E-mail	abc@abc.com	Website	www.abc.co.kr
Import	Yes	Export	Yes
Line of Business	Manufacture of medicaments, Manufacture of medical and dental instruments and supplies, Manufacture of health functional foods		
SIC	2833-0100 / 3841-0000 / 5149-0602		
Parent Company	▷ Name : N/A		
	▷ Country : N/A		
	▷ Share hold (%) : N/A		

Currency: All Monetary shown in KOREAN MILLION Won unless otherwise stated.
Exchange Rate of The Latest Fiscal Year (as of 2023/12/31) : 1,308.9 KRW/USD

Current Investigation

On 2024/10/30, Kim, Chul Soo, the general manager, confirmed operational & historical information. The financial statement(s) of subject was obtained from it's annual report, and other information was obtained from the third-party source.

Executive Summary

Subject company is a Corp.-Public Limited Company established in 1954 with 1,002 employees.

Subject company's registered capital is KRW 6,881 mil.

Subject company has 0 media record(s) in the past 12 months.


The subject company recorded operating losses based on its FY2023 financial statement.

Media Release

Date	
Source	
Details	N/A

D&B Risk Assessment

D&B Rating

5A1	 <p>Net Worth 5A</p>	<p>The D&B Rating for the subject is 5A1 which indicates a tangible net worth more than KRW 35,515,000,000.</p> <p>And an overall credit condition which is considered strong.</p>
------------	--------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CLIP Risk Analysis

A	<table><tr><td>NO GRADE</td><td>RISK</td><td>WATCHFUL</td><td colspan="3">USUAL</td><td colspan="4">SUPERIOR</td></tr><tr><td colspan="10" style="text-align: right;">▼</td></tr><tr><td>NG</td><td>D</td><td>C</td><td>CC</td><td>CCC</td><td>B</td><td>BB</td><td>BBB</td><td>A</td><td>AA</td><td>AAA</td></tr></table>	NO GRADE	RISK	WATCHFUL	USUAL			SUPERIOR				▼										NG	D	C	CC	CCC	B	BB	BBB	A	AA	AAA
	NO GRADE	RISK	WATCHFUL	USUAL			SUPERIOR																									
	▼																															
NG	D	C	CC	CCC	B	BB	BBB	A	AA	AAA																						
The CLIP Risk Analysis for the subject is A. Based on this Analysis, the subject is judged to “High level of credibility for short-term business. However, has limited ability in corresponding to presumable changes in circumstances.” Credibility of the subject is considered as the superior level of in the peer group.																																

Failure Score

1	2	3	4	NG
		35		
Low Risk(100)				High Risk(1)
Failure Score Class	Percentile Score		Failure Score	Probability of Failure
3	35		1,416	1.01
Dun and Bradstreet Failure Score predicts the likelihood that a business will go bankrupt in the next 12 months. Dun and Bradstreet defines a bankrupt business as a Failed Business. Dun and Bradstreet Failure Score predicts the likelihood of such a Failure.				

• Key Influencing Factors for Failure Score

The Failure Score Class for this company is calculated for the following reason.

- Factors related to Liquidity are bad.
- Factors related to Leverage are average.
- Financial expenses to total assets ratio is average.
- Factors related to Debt Redemption are average.
- Subject company has a high number of loans.
- Subject company has a low annual resignation rate.
- Subject company has a high Financial Reliability Index.
- Subject company has a high Cash Flow Rating.
- Subject company has very low capability to raise funds from financial institutions.
- Subject company has a long history.
- Subject company has a low Sales/Purchase Index.
- Loan ratio for the Non-Banks(non-primary financial institutions) is average.

Brief Financial Summary

*Note : If F/S are not obtainable, this section is substituted to financial ratio analysis on industry average.

(Unit : KRW Mil., %)

Item	2021/12	2022/12	2023/12	Financial Ratios	2021/12	2022/12	2023/12
Total Assets	828,222	888,665	838,744	Growth Rate of Net Income	29.1	57.3	-112.1
Total SH' Equity	385,374	403,014	388,572	SHs' Equity to Total Assets	46.5	45.4	46.3
Capital Stock	6,882	6,882	6,882	Debt to Equity	114.9	120.5	115.9
Total Borrowings	258,174	297,847	299,816	Total Borrowings and Debentures Payables to Total Assets	31.2	33.5	35.7
Financial Exp.	5,755	8,224	13,771	Financial Exp. to Sales	1.1	1.5	2.7
Sales	511,148	536,574	518,002	Growth Rate of Sales	2.8	5.0	-3.5
Operating Income	28,930	29,103	13,876	Operating Income to Sales	5.7	5.4	2.7
Net Income	11,335	17,835	-2,151	Net Income to Sales	2.2	3.3	-0.4

Finance

*Note : If F/S are not obtainable, this section is substituted to financial ratio analysis on industry average.

Statement of Financial Position

(Unit : KRW Mil., %)

Account	2021/12			2022/12			2023/12		
	Amount	%	Growth	Amount	%	Growth	Amount	%	Growth
Current Assets	320,239	38.7	-1.1	342,009	38.5	6.8	283,154	33.8	-17.2
Quick Assets	236,973	28.6	-2.0	250,272	28.2	5.6	189,665	22.6	-24.2
Cash & Cash Equivalent	27,285	3.3	25.3	28,773	3.2	5.5	10,167	1.2	-64.7
S/T Investments	0	-	-	0	-	-	0	-	-
Trade Receivables	163,783	19.8	-1.6	165,061	18.6	0.8	138,992	16.6	-15.8
Other Receivables	7,008	0.9	22.2	6,249	0.7	-10.8	26,622	3.2	326.0
Advance Payments	29,414	3.6	-13.8	43,967	5.0	49.5	11,029	1.3	-74.9
Prepaid Expense	2,839	0.3	-21.9	3,311	0.4	16.6	1,774	0.2	-46.4
Other Quick Assets	6,643	0.8	-34.6	2,911	0.3	-56.2	1,080	0.1	-62.9
Inventories	83,266	10.1	1.6	91,737	10.3	10.2	93,490	11.2	1.9
Non-current Assets	507,983	61.3	7.5	546,656	61.5	7.6	555,589	66.2	1.6
Investments	231,186	27.9	2.0	253,529	28.5	9.7	256,005	30.5	1.0
L/T Financial Instruments	40,936	4.9	31.8	45,832	5.2	12.0	35,225	4.2	-23.1
Other Investments	190,250	23.0	-2.7	207,697	23.4	9.2	220,780	26.3	6.3
Tangible Assets	210,349	25.4	20.0	219,687	24.7	4.4	223,140	26.6	1.6
Land	60,916	7.4	-6.7	64,978	7.3	6.7	66,849	8.0	2.9
Assets for Depreciation	142,382	17.2	57.0	146,540	16.5	2.9	141,570	16.9	-3.4
Construction in-Progress	7,051	0.9	-63.6	8,168	0.9	15.8	14,720	1.8	80.2
Other Tangible Assets	0	-	-	0	-	-	0	-	-
Intangible Assets	65,372	7.9	-5.3	70,496	7.9	7.8	73,197	8.7	3.8
Other Non-current Assets	1,077	0.1	-24.6	2,944	0.3	173.4	3,248	0.4	10.3
Housing Assets for Rent	0	-	-	0	-	-	0	-	-
Total Assets	828,222	100.0	4.0	888,665	100.0	7.3	838,744	100.0	-5.6
Current Liabilities	276,094	33.3	22.3	269,620	30.3	-2.3	300,280	35.8	11.4
Trade Payables	91,733	11.1	-1.1	107,645	12.1	17.4	81,415	9.7	-24.4
Short Term Borrowings	118,699	14.3	139.1	77,869	8.8	-34.4	125,177	14.9	60.8
Advance Receipts	650	0.1	13.0	538	0.1	-17.2	2,218	0.3	312.3
Accrued Expenses	8,591	1.0	-48.4	9,063	1.0	5.5	3,092	0.4	-65.9
Accrued Income Taxes	4,425	0.5	-60.4	4,964	0.6	12.2	292	-	-94.1
Current Portion of L/T Liabilities	0	-	-	34,883	3.9	-	49,881	6.0	43.0
Other Current Liabilities	56,421	6.8	56.2	39,622	4.5	-29.8	38,497	4.6	-2.8
Non-current Liabilities	166,755	20.1	-13.7	216,032	24.3	29.6	149,892	17.9	-30.6
Debentures	84,076	10.2	144.1	49,644	5.6	-41.0	24,010	2.9	-51.6
Long-Term Borrowings	55,399	6.7	-53.5	135,451	15.2	144.5	100,748	12.0	-25.6
Provision for S&R Benefits	3,360	0.4	-41.0	0	-	-	0	-	-
Other Non-Current Liabilities	23,919	2.9	-29.5	30,937	3.5	29.3	25,134	3.0	-18.8
Total Liabilities	442,849	53.5	5.7	485,652	54.7	9.7	450,172	53.7	-7.3
Capital Stock	6,882	0.8	0.0	6,882	0.8	0.0	6,882	0.8	0.0
Capital Surplus	38,540	4.7	0.0	38,540	4.3	0.0	38,540	4.6	0.0
Retained Earnings	299,817	36.2	2.7	317,797	35.8	6.0	303,502	36.2	-4.5
(Net Income)	11,335	1.4	29.1	17,835	2.0	57.3	-2,151	-0.3	-112.1
Capital Adjustments	254	-	0.0	254	-	0.0	254	-	0.0
Other Accu. Comprehensive Income	39,880	4.8	0.8	39,540	4.5	-0.9	39,393	4.7	-0.4
Total Stockholders' Equity	385,374	46.5	2.2	403,014	45.4	4.6	388,572	46.3	-3.6
Total Liabilities & Capital	828,222	100.0	4.0	888,665	100.0	7.3	838,744	100.0	-5.6
Total Borrowings *	258,174	31.2	10.7	297,847	33.5	15.4	299,816	35.8	0.7

*Note: Total borrowings include Long-Term Trade Payables and Long-Term Accounts Payables.

Income Statement

(Unit : KRW Mil., %)

Account	2021/12			2022/12			2023/12		
	Amount	%	Growth	Amount	%	Growth	Amount	%	Growth
Sales	511,148	100.0	2.8	536,574	100.0	5.0	518,002	100.0	-3.5
Cost of Sales	346,811	67.9	4.4	366,792	68.4	5.8	354,765	68.5	-3.3
Gross Income	164,338	32.2	-0.5	169,783	31.6	3.3	163,237	31.5	-3.9
S&A Expenses	135,408	26.5	0.6	140,679	26.2	3.9	149,361	28.8	6.2
Salaries	45,681	8.9	-1.7	46,611	8.7	2.0	48,224	9.3	3.5
S&R Benefits	4,794	0.9	-8.5	5,686	1.1	18.6	4,300	0.8	-24.4
Employee Benefits	0	-	-	0	-	-	0	-	-
Taxes and Dues	0	-	-	0	-	-	0	-	-
Rent	0	-	-	0	-	-	0	-	-
Depreciation	6,555	1.3	3.7	6,297	1.2	-3.9	6,343	1.2	0.7
Amortization Expenses on intangible Assets	2,374	0.5	-5.1	2,086	0.4	-12.1	2,359	0.5	13.1
Advertising Expense	11,690	2.3	-5.1	11,479	2.1	-1.8	13,897	2.7	21.1
Bad Debt Expenses	-62	-0.0	-487.5	65	-	204.8	-6	-	-109.2
Commission Fee	19,857	3.9	-6.6	20,427	3.8	2.9	20,176	3.9	-1.2
R&D Expenses	28,104	5.5	16.2	30,145	5.6	7.3	35,607	6.9	18.1
Others	16,414	3.2	0.9	17,882	3.3	8.9	18,461	3.6	3.2
Operating Income	28,930	5.7	-5.2	29,103	5.4	0.6	13,876	2.7	-52.3
Non-Operating Income	20,327	4.0	13.7	28,377	5.3	39.6	18,280	3.5	-35.6
Interest Income	430	0.1	-36.9	467	0.1	8.6	1,383	0.3	196.2
Dividends Income	437	0.1	-	0	-	-	0	-	-
Gains on Foreign Currency Transaction	536	0.1	-59.5	1,580	0.3	194.8	2,765	0.5	75.0
Gains on Foreign Currency	52	-	-99.0	3,838	0.7	7,280.8	246	0.1	-93.6
Equity Method Income	0	-	-	0	-	-	0	-	-
Gains on Disposition of Investment	0	-	-	0	-	-	0	-	-
Gains on Disposition of Tangible Assets	3,837	0.8	611.9	264	0.1	-93.1	82	-	-68.9
Reversal of Allowance for Bad	0	-	-	0	-	-	0	-	-
Others	15,034	2.9	49.6	22,227	4.1	47.8	13,803	2.7	-37.9
Non-Operating Expenses	33,227	6.5	20.9	36,864	6.9	11.0	35,316	6.8	-4.2
Interest Expense	5,755	1.1	-14.8	8,224	1.5	42.9	13,771	2.7	67.5
Losses on Foreign Currency Transaction	1,005	0.2	-19.3	3,661	0.7	264.3	991	0.2	-72.9
Losses on Foreign Currency Translation	4,879	1.0	19,416.0	1,921	0.4	-60.6	737	0.1	-61.6
Equity Method Losses	0	-	-	0	-	-	0	-	-
Losses on Disposition of Investment	0	-	-	0	-	-	0	-	-
Losses on Disposition of Tangible Assets	67	-	-60.8	81	-	20.9	7	-	-91.4
Others	21,520	4.2	11.6	22,977	4.3	6.8	19,809	3.8	-13.8
Ongoing Biz. Income Before Income Taxes	16,030	3.1	-23.3	20,616	3.8	28.6	-3,160	-0.6	-115.3
Income Tax Expenses for Ongoing Biz.	4,695	0.9	-61.3	2,781	0.5	-40.8	-1,009	-0.2	-136.3
Ongoing Biz. Income	11,335	2.2	29.1	17,835	3.3	57.3	-2,151	-0.4	-112.1
Discontinued Biz. Income	0	-	-	0	-	-	0	-	-
Net Income	11,335	2.2	29.1	17,835	3.3	57.3	-2,151	-0.4	-112.1

Auditor's Opinion & Source of F/S :2021 Auditor's Opinion: Unqualified, 2022 Auditor's Opinion: Unqualified, 2023 Auditor's Opinion: Unqualified.

Manufacturing Cost Statement

(Unit : KRW Mil., %)

Account	2021/12			2022/12			2023/12		
	Amount	%	Growth	Amount	%	Growth	Amount	%	Growth
Cost of Materials	202,464	76.9	5.1	233,684	76.4	15.4	0	-	-
Labor Costs	17,355	6.6	4.8	20,624	6.7	18.8	0	-	-
Salaries	15,515	5.9	3.3	18,323	6.0	18.1	0	-	-
Severance and Retirement Benefits	1,839	0.7	19.3	2,301	0.8	25.1	0	-	-
Expenses	43,606	16.6	-0.7	51,491	16.8	18.1	0	-	-
Depreciation	6,477	2.5	0.8	6,896	2.3	6.5	0	-	-
Taxes and Dues	850	0.3	5.3	955	0.3	12.4	0	-	-
Employee Benefits	1,640	0.6	4.3	1,887	0.6	15.1	0	-	-
Rent	29	-	-17.1	30	-	3.5	0	-	-
Outside Processing Expense	5,358	2.0	-36.5	1,551	0.5	-71.1	0	-	-
Others	29,253	11.1	9.9	40,172	13.1	37.3	0	-	-
Total Mfg. Overhead	263,424	100.0	4.1	305,798	100.0	16.1	0	-	-
Beginning Work-in Process	2,605	1.0	-42.4	3,674	1.2	41.0	0	-	-
Ending Work-in Process	3,674	1.4	41.0	2,451	0.8	-33.3	0	-	-
Transfers-In	-2,457	-0.9	7.3	-195	-0.1	92.1	0	-	-
Cost of Goods Manufactured During the Year	259,898	98.7	3.0	306,826	100.3	18.1	0	-	-
Beginning Inventory	23,363	8.9	7.9	20,896	6.8	-10.6	23,815	-	14.0
Transfers-In	0	-	-	0	-	-	0	-	-
Ending Work-In Process	20,896	7.9	-10.6	23,815	7.8	14.0	27,331	-	14.8
Cost of Sales	123,676	47.0	1.3	140,588	46.0	13.7	136,198	-	-3.1

Finance

*Note : If F/S are not obtainable, this section is substituted to financial ratio analysis on industry average.

Financial Ratios

(Unit : %, Time)

Item	Arithmetic Expression	2022/12	2023/12	Avg. of same Ind.
<Profitability>				
Net Income to SHs' Equity	Net Income/(SHs' Equity in former term+SHs' Equity in this term)x200	4.5	-0.5	8.0
Net Income to Total Assets	Net Income/(Total Assets in former term+Total Assets in this term)x200	2.1	-0.2	5.2
Net Income to Sales	Net Income/Sales x 100	3.3	-0.4	8.9
Interest Coverage Ratio	(Operating Income/Interest Expenses)x100	353.9	100.8	1,062.4
Financial Exp. to Sales	Financial Exp./Sales x 100	1.5	2.7	1.2
Cost of Sales to Sales	Cost of Sales/Sales x 100	68.4	68.5	57.2
Capital Surplus and R/E to SHs' Equity	(Capital Surplus+R/E)/ SHs' Equity x 100	88.4	88.0	-
Operating Income to Sales	Operating Income/Sales x 100	5.4	2.7	12.9
<Stability>				
Current Ratio	Current Assets/Current Liabilities x 100	126.8	94.3	196.9
Non-current Assets to SHs' Equity & Non-current Liab.	Non-current Assets / (SHs' Equity + Non-current Liabilities) x 100	88.3	103.2	69.5
Debt to Equity Ratio	Total Liabilities/SHs' Equity x 100	120.5	115.9	52.8
SHs' Equity to Total Assets	SHs' Equity/Total Assets x 100	45.4	46.3	65.4
Total Borrowings and Debentures Payables to Total Assets	Total Borrowings/Total Assets x 100	33.5	35.7	16.8
Quick Ratio	Quick Assets/Current Liabilities x 100	92.8	63.2	146.6
<Turnover Ratios>				
Working Capital Turnover	Sales/Average of Working Capital	3.5	3.5	2.9
Trade Payables Turnover	Sales/Average of Trade Payables	5.4	5.5	16.9
Trade Receivables Turnover	Sales/Average of Trade Receivables	3.3	3.4	5.2
Inventories Turnover	Sales/Average of Inventories	6.1	5.6	4.8
Total Assets Turnover	Sales/Average of Total Assets	0.6	0.6	0.6
<Growth Ratios>				
Growth Rate of SHs' Equity	SHs' Equity in this term/SHs' Equity in former term x 100-100	4.6	-3.6	15.7
Growth Rate of Operating Income	Operating Income in this term/Operating Income in former term x 100-100	0.6	-52.3	-
Growth Rate of Total Assets	Total Assets in this term/Total Assets in former term x 100-100	7.3	-5.6	13.2
Growth Rate of Sales	Sales in this term/Sales in former term x 100-100	5.0	-3.5	7.8
Growth Rate of Net Income	(Net Income in this term/Net Income in former term)x100-100	57.3	-112.1	-

*Note: Source of Industrial Average : (C21000) Manufacture of pharmaceuticals, medicinal chemical and botanical products, The

FINANCIAL ANALYSIS

After recording sales of KRW 511,148 mil. in FY2021, the subject company was fluctuating on sales over the last two years, recording sales of KRW 536,574 mil. which increased by 5.0% in FY2022 and recording sales of KRW 518,002 mil. which decreased by 3.5% in FY2023.

In FY2023, although the cost to sales to sales ratio maintained at the same level as in the previous year, the operating income to sales fell from 5.4% to 2.7% as the SG&A expenses rose. Due to the decline in operating profitability in FY2023, the net income to sales turned into a deficit of -0.4%, and overall profitability deteriorated.

Although stockholders'(SHs') equity decreased in FY2023, the debt to equity ratio fell from 120.5% to 115.9% and the total SHs' equity to total assets rose from 45.4% to 46.3% as total liabilities decreased further, and overall financial stability improved from the previous year.

Meanwhile, total borrowings to total assets ratio rose from 33.5% to 35.7% in FY2023 and the subject company's financial risk became higher than the previous year, having excessive borrowings compared to the amount of total assets.

* The subject's brief financial summary until the 2nd quarter of FY2024 is as follows: [KRW mil.]

Total assets	Net worth	Sales	Operating income	Net income
840,176	382,637	253,479	7,114	-1,883

Until the 2nd quarter of FY2024, it recorded KRW 253,479 mil. which is decreased in 5.1% compared to the corresponding period of last year. In addition, half-year operating profit compared to sales was 2.8% and turned into red figure.

Bank

The company maintains relationship(s) with the following bank(s) in Korea:

DEUTSCHE BANK AG

Seoul Branch

Borrowings

As of 2024/06/30 (Unit: KRW, mil.)

Creditor	Long/Short Term	Discounted Notes		Remark
		Limit	Balance	
Loans(Banks, etc.)	270,430	-	-	
Bond	58,260	-	-	-
Financial Lease	1,743	-	-	-

Detrimental Information

As of 2024/11/01 (Unit: KRW Thou.)

Business Not Reported

Date of Event

Initial Date

Dissolution Date

No. of Note

No. of Institutes

Total Amount

The Reason of detrimental information

Corporate Not Reported

Date of Event

Initial Date

Dissolution Date

No. of Note

No. of Institutes

Total Amount

The Reason of detrimental information

President 1 Not Available

Date of Event

Initial Date

Dissolution Date

No. of Note

No. of Institutes

Total Amount

The Reason of detrimental information

Note: Detrimental Information is sourced from National Information & Credit Evaluation (NICE) Ltd. which is an authorized Credit Bureau in Korea with more than 160 financial and non-financial institutions such as banks, credit card companies, capital, leasing, factoring, distribution companies and many others including Korea Credit Information Service, contributing their data into NICE Credit Bureau. NICE collates various kinds of negative information such as bankruptcy, payment delinquency, etc.

Date of Event: The date which major detrimental information occurred

Initial The date in which such relevant financial organization as banks, and credit card companies provided

Date: the negative information with NICE, an authorized CB(Credit Bureau) in Korea

Dissolution Date: The date of detrimental information dissolved

No. of Note: Total number of negative credit event

No. of Institutes: Total number of financial organizations such as banks, credit card companies which disclosed detrimental information

Total Amount: The sum of Arrears, Subrogation, Substitute Payment, and etc

The Reason of detrimental information: Description of detrimental information

History

Registration Date : 1958/08/19
 Corporate Registration No. : 110111-1000000
 Business Registration No. : 123-45-67890
 Registered Capital : KRW 6,882 mil.
 Net Worth : KRW 388,572 mil.
 Business Start Year : 1954
 Legal Status : Corp.-Public Limited Company

Other key event

1954/04/27 : Established as the name of AB Co.
 1958/08/19 : Incorporated as the name of AB Co., Ltd.
 1976/06/30 : Listed on Korea Stock Exchange.
 1995/03/10 : Changed its name to ABC Co.,Ltd.
 2003/05/01 : Stock split: par value from KRW 5,000won to KRW 500won.
 2014/01/01 : Due to the implementation of new address system based on road name address, its head office address was changed from 735, Yeoksam-dong, Gangnam-gu, Seoul to 132, Teheran-ro, Gangnam-gu, Seoul. It is only change in expression by new address system but not change in physical location.
 2018/01/22 : Increased its capital to KRW 6,882 Mil.
 2021/03/01 : Merged with DEF Co., Ltd.

Shareholders' List

As of 2024/06/30

Name of SH	No. of Shares	Ratio(%)	Amount(KRW Mil.)	Relation with Majority SH
Hong, Gil Dong	1,878,397	13.7	939	(Chairman/President)
ABCD Co., Ltd.	2,435,290	17.7	1,218	The Majority shareholder(Affiliated Company)
Others	9,449,846	68.6	4,725	-
Total	13,763,533	100.0	6,882	

Principals

Details of director(s) are listed as follows:

Name(ENG)	:	Hong, Gil Dong
Date of Birth	:	1956/10/10
Title	:	Chairman/President
Full-time Status	:	YES
Area of Responsibility	:	Overall Management

Employment History

Period	Company Employed	Last Position Held
1984 - 1991	ABC Co., Ltd.	General Manager
1991 - 1992	ABC Co., Ltd.	Managing Director
1992 - 1996	DEF Co., Ltd.	Vice-president
1995 - 1996	ABC Co., Ltd.	Vice-president
1996 - Current	ABC Co., Ltd.	Chairman/President

Operation

Subject is engaged in

Manufacture of medicaments

Products / Services

Medicine(Amaryl, Soliris, Ketotop etc.)	: 75.9%
Regents & Medical appliances	: 15.6%
Consumer Health	: 2.0%
Others	: 6.5%

PURCHASE TERRITORY

Local	: 53.0%
International	: 47.0%
Import from	: Singapore, Japan, UK

MAJOR SUPPLIERS

Name	Product(s)/Service(s) bought	PURCHASING TERMS
AAA Co., Ltd.	Raw materials	Cash
BBB Co., Ltd.	Raw materials	Cash
CCC Co., Ltd.	Raw materials	Cash
DDD Co., Ltd.	Raw materials	Cash

SALES TERRITORY

Local	: 98.0%
International	: 2.0%
Export to	: Singapore, Malaysia, PR China

MAJOR CUSTOMERS

Name	Product(s)/Service(s) sold	SELLING TERMS
AA Co., Ltd.	Amaryl, Soliris etc	Cash
BB Co., Ltd.	Amaryl, Soliris etc	Cash
CC Co., Ltd.	Amaryl, Soliris etc	Cash
FF Co., Ltd.	Amaryl, Soliris etc	Cash

TOTAL EMPLOYEES	1,002 (As of 2024/06/30)
Director	23
Officer	-
Technical post	-
Production worker	-
Other	979

Operation Analysis

1. Company Profile

ABC Co., Ltd. was founded in April, 1954 with the purpose of manufacture of medicaments. It was founded as the name of AB Co. in 1954 and changed the current name in 1995. It listed on Korea Stock Exchange in June, 1976. The company is Corp.-Public Limited Company with total assts of KRW 838,744 Mil. as of Dec. 31, 2023, annual sales of KRW 518,002 Mil. in FY2023, 1,002 employees as of Jun. 30, 2024.

2. Management

Hong, Gil Dong, the chairman and president of the company, was born in 1956. He inaugurated as the president of the company in Feb, 1996, succeeding his father and has been responsible for overall management up to now.

As of Jun, 2024, its paid-in capital is KRW 6,882 Mil. and ABCD Co., Ltd. holds 17.7% of shares as the largest shareholder. Meanwhile, as the chairman and president, Hong, Gil Dong, holds 13.7% of the shares.

3. Operations

The subject is engaged in manufacture of medicaments, manufacture of medical and dental instruments and supplies, and manufacture of health functional foods. It has the headquarter located at ***, Teheran-ro, Gangnam-gu, Seoul. and the Factory located at ***, *****-ro, Daeso-myeon, Eumseong-gun, Chungcheongbuk-do.

Its business divided into three divisions-medicines(Ketotop, Ultomiris, Amaryl, etc.), medical appliances(diagnostic instrument and reagent such as BEP III etc.) and health functional foods(Consumer Health including Nature Set, Ready-Q, etc.). In FY2023, Medicines consist of 75.9% of total sales, Regents & Medical appliances tijj 15.6%, Consumer Health took 2.0% and rest 6.5% took others.

Its major customers are AA Co., Ltd., BB Co., Ltd., CC Co., Ltd., FF Co., Ltd, etc. And its major suppliers are AAA Co., Ltd., BBB Co., Ltd., CCC Co., Ltd., DDD Co., Ltd., etc. It exports its products to Singapore, Malaysia, PR China, with 2.0% export ratio in FY2023.

Linkage

Ultimate Parent

D-U-N-S	:	Not applicable
Name	:	
Country	:	
Started	:	
Total Assets	:	
Sales	:	
Net Income	:	
Total SH' Equity	:	
Capital	:	
Fiscal Year	:	

Parent Company

D-U-N-S	:	Not applicable
Name	:	
Country	:	
% Share Hold	:	
Started	:	
Total Assets	:	
Sales	:	
Net Income	:	
Total SH' Equity	:	
Capital	:	
Fiscal Year	:	

Affiliated Companies

D-U-N-S	:	68-000-0001
Name	:	ABCD Co., Ltd. v
Country	:	Korea (South)
Relationship with subject	:	17.7% of Shares Held in Subject
Started	:	2001
Total Assets	:	-
Sales	:	-
Net Income	:	-
Total SH' Equity	:	-
Capital	:	-
Fiscal Year	:	2023

D-U-N-S	:	66-000-0001
Name	:	ABC(HK) Co., Ltd.
Country	:	Hong Kong
Relationship with subject	:	100% of Shares Owned by Subject
Started	:	-
Total Assets	:	KRW 147 mil.
Sales	:	KRW 0 mil.
Net Income	:	KRW -1 mil.
Total SH' Equity	:	KRW 128 mil.
Capital	:	KRW 636 mil.
Fiscal Year	:	2023

D-U-N-S	:	71-000-0001
Name	:	ABC J Corporation
Country	:	Japan
Relationship with subject	:	100% of Shares Owned by Subject
Started	:	-
Total Assets	:	KRW 6,334 mil.
Sales	:	KRW 5,035 mil.
Net Income	:	KRW 311 mil.
Total SH' Equity	:	KRW 4,936 mil.
Capital	:	KRW 1,037 mil.
Fiscal Year	:	2023

D-U-N-S	:	55-000-0001
Name	:	ABCDE Co., Ltd.
Country	:	Korea (South)
Relationship with subject	:	73% of Shares Owned by Subject
Started	:	2008
Total Assets	:	KRW 3,528 mil.
Sales	:	KRW 0 mil.
Net Income	:	KRW -3,586 mil.
Total SH' Equity	:	KRW 2,655 mil.
Capital	:	KRW 1,572 mil.
Fiscal Year	:	2023

Branches

Nature of Business : Factory
Address : ***, *****-ro, Daeso-myeon, Eumseong-gun,
Chungcheongbuk-do

Nature of Business : Laboratory
Address : ***, *****-ro, Gangseo-gu, Seoul

Nature of Business : Sales Office
Address : ***, *****-ro, Seo-gu, Daejeon

CLIP Analysis Definition

Classification	Rating	Description	Est. Rate of Failure
SUPERIOR	AAA	Highest level of credibility for short-term business. Superior level of credibility which can correspond to any changes in circumstance within the rational estimation that can be made at current status.	0.00%
	AA	Very high level of credibility for short-term business. May correspond to changes in circumstances that could be assumed.	0.82%
	A	High level of credibility for short-term business. However, has limited ability in corresponding to presumable changes in circumstances.	1.35%
USUAL	BBB	Adequate level of credibility for short-term business. However, possessed with relatively negative factors in business stability for the future.	2.92%
	BB	Moderate level of credibility for short-term business. However, possessed with relatively negative factors in business stability for the future.	4.06%
	B	May be acknowledged for short-term credibility. However, possessed with possibility of reimbursement guarantee degraded in case of environmental change.	5.12%
WATCHFUL	CCC	Very limited credibility at present and presumed to degrade long-term business stability. Called to attention.	6.29%
	CC	Has possibility of default. Business stability is very low compared to above classes.	7.57%
RISK	C	High possibility of default. Low possibility of recovery in the future. The level of which reimbursement ability is doubted.	11.84%
	D	The subject defaulted or is facing impending default. Credit should be denied.	Over 68.46%
NO GRADE	NG	No Grade: Reservation of judgment due to lack of information, decline of credit evaluation, cessation of business, suspend business and others.	

Features of CLIP Evaluation System

CLIP Evaluation System is a credibility evaluation system with high accuracy developed with diverse evaluation and statistical information of National Information & Credit Evaluation, Inc. (NICE), the biggest credibility evaluation company and specialist in RISK MANAGEMENT

1. CLIP Non-Financial Evaluation System reflects evaluations of credibility evaluator about production competitiveness, marketing competitiveness, management capability, etc according to the types of standard industry category.
2. CLIP Financial Evaluation System is “an Evaluation System following financial statement” provided by our company, which provided credibility evaluation information for long time.
3. CLIP Analysis combines non-financial evaluation system, financial evaluation system as well as our experienced Business Analysts’ subjectivity which assess all circumstances surrounding the subject.
4. Estimated rate of failure is generated from very high level of accuracy using a failure forecasting system applied to the subjects.

Key to Failure Score

Risk Class	% of Businesses within range	Failure Score Percentile	Failure Score	Probability of Failure
1	9.95%	91-100	1574-1999	0.03%
2	40.37%	52-90	1443-1573	0.24%
3	38.92%	11-51	1345-1442	1.01%
4	10.76%	1-10	1001-1344	4.95%

Features of Failure Score Evaluation

Dun and Bradstreet Failure Score predicts the likelihood that a business will go bankrupt in the next 12 months. Dun and Bradstreet defines a bankrupt business as a Failed Business. Dun and Bradstreet Failure Score predicts the likelihood of such a Failure.

1. The Failure Score Class indicates that this company shares some of the same business and financial characteristics of other companies with this classification. It does not mean the firm will necessarily experience financial distress.
2. The Failure Score Percentile reflects the relative ranking of a company among all scoreable companies in D&B database.
3. The Failure Score offers a more precise measure of the level of risk than the Class and Percentile. It is specially helpful to customers using a scorecard approach to determine overall business.
4. All Failure Score Class, Percentile, Score and Incidence statistics are based on latest analysis derived from NICE D&B database.
5. The legal events which constitute failure in Korea include:
 - Arrears: All types of delayed payments regarding financial transaction
 - Subrogation/ proxy payment: Subrogation or proxy payment occurred
 - Bankruptcy: Dishonored bill or check
 - Negative Public information: Delayed payments for National tax, regional tax, fine, and/or tele communication bill
 - Breach of financial order : Wrongful financial transaction, Violation of exchange transactions, and export insurance accidents
 - Special case : Court receivership, rehabilitation, and etc.

FULL DISPLAY COMPLETE

This report is provided strictly for internal use by the subscriber in accordance with the terms of the subscription contract.

Re-distribution or re-selling of this report for use by companies other than the subscriber is prohibited.